About DrugAbuse Sciences
DrugAbuse Sciences is a company based in Menlo Park (United States) founded in 1994 was acquired by Elbion in January 2007. DrugAbuse Sciences offers products and services including Naltrexone Depot and Addiction Medications. DrugAbuse Sciences operates in a competitive market with competitors including Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
- Headquarter Menlo Park, United States
- SectorsHealthcare
- Website drugabusesciences.com
- Social LinkedIn
- Acquired by Elbion (Jan 2007)
- Legal Name Drugabuse Sciences, Inc.
Products & Services of DrugAbuse Sciences
DrugAbuse Sciences offers a comprehensive portfolio of products and services, including Naltrexone Depot and Addiction Medications.
Injection for treating alcohol dependence and reducing cravings.
Develops drugs to address substance abuse disorders.
Investors in DrugAbuse Sciences
DrugAbuse Sciences has secured backing from 1 investor. Prominent investors backing the company include Elbion.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Small molecules for CNS and inflammatory diseases were discovered. | 2002 | elbion.com | Radebeul, Germany |
Investor details for DrugAbuse Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of DrugAbuse Sciences
2 dated milestones of DrugAbuse Sciences across 13 years, from founding to its latest funding, stage changes and deals.
- Founded DrugAbuse Sciences is founded.
- Exit Acquired by Elbion.
Competitors of DrugAbuse Sciences
DrugAbuse Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indivior, Biotie, Ethypharm, Braeburn and Opiant Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| indivior.com | 2014 | Richmond Hill, United States | – | 1,051 | Therapeutics for opioid addiction treatment are developed and commercialized. | |
| biotie.com | 1998 | Turku, Finland | $149.81M | 27 | Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| braeburnrx.com | 2012 | Philadelphia, United States | $110M | – | Long-acting therapies for opioid addiction and chronic pain are developed. | |
| opiant.com | 2005 | Santa Monica, United States | – | 31 | Therapeutics for addictive and eating disorders are developed. | |
| amygns.com | 2015 | San Francisco, United States | $7.05M | – | Therapies for substance use disorders are developed by Amygdala Neurosciences. | |
| 4p-pharma.com | 2014 | Lille, France | $18.49M | – | French Biotech startup that develops to clinical trial stage the molecules it has in-licensed | |
| cessationtherapeutics.com | 2017 | San Jose, United States | $6.76M | – | Developer of immunotherapy based vaccines to manage addictions | |
| titanpharm.com | 1992 | San Francisco, United States | – | 11 | A specialty pharmaceutical company developing proprietary therapeutics for select chronic diseases | |
| aelisfarma.com | 2013 | Bordeaux, France | $14.04M | – | Developer of small molecule drugs targeting CB1 receptor for CNS diseases |
Detailed competitors of DrugAbuse Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to DrugAbuse Sciences
10 companies that operate in the same segment as DrugAbuse Sciences (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about DrugAbuse Sciences
DrugAbuse Sciences was founded in 1994.
DrugAbuse Sciences is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
DrugAbuse Sciences was founded in 1994 in Menlo Park, United States, as a specialty pharmaceutical company focused on addiction treatments. Therapies targeting alcohol, opiate, cocaine, and heroin dependencies are developed and commercialized. Key products include Naltrexone Depot for alcohol and opiate addictions, DAS-431 for cocaine addiction, and Buprenorphine for heroin and opiate use. Company assets were acquired by Elbion in January 2007, now integrated into Biotie.
DrugAbuse Sciences's top competitors include Indivior, Ethypharm and Amygdala Neurosciences.
DrugAbuse Sciences offers Naltrexone Depot and Addiction Medications.
DrugAbuse Sciences has 1 investor. Key investors include Elbion.
DrugAbuse Sciences operates through Drugabuse Sciences, Inc..
Yes. DrugAbuse Sciences was acquired by Elbion in January 2007.